This plasma-glycated CD59 (pGCD59), measurable by flow cytometry, is used as a diabetes biomarker, and has recently been shown to be specific for GDM determination, even before the 20th week of gestation (93-95). This evidence concerns the gene CD59 and diabetes mellitus.